Introducing our new Chief Investment Officer, Charlie Lanchester

We would like to introduce our new Chief Investment Officer, Charlie Lanchester. Charlie has significant funds management experience and thrilled to be joining the HM1 team.

Introducing our new Chief Investment Officer, Charlie Lanchester

April 10, 2023
We would like to introduce our new Chief Investment Officer, Charlie Lanchester. Charlie has significant funds management experience and thrilled to be joining the HM1 team.
Read Transcript

Hi everyone,

I am delighted to introduce myself as the new Chief Investment Officer of Hearts and Minds Investments. My name is Charlie Lanchester, and I have spent the last 30 years working in the investment industry as a portfolio manager, both in Australia and the UK. I am thrilled to be joining the Hearts and Minds team and look forward to contributing to the growth and success of the fund.

I am aware that the fund has faced some short-term challenges, with a decline in performance contributing to the current share price trading at a significant discount to the net tangible assets (NTA) of the portfolio. While this is disappointing, I feel confident that the underlying investments are sound and that this represents an opportunity to buy some great quality companies at below market price. As an organisation, we have access to some of the brightest minds in the industry, both here in Australia and in global markets. The mix of stocks across sectors and geographies makes this investment proposition quite unique and a great addition to any portfolio. We have a strong bench of talented investment professionals, and I look forward to working closely with them in the coming years.

We are in the process of curating this year's conference, which will return to Sydney on Friday 17th November. We have approached some exciting new fund managers with a particular focus on global opportunities now that travel has become a little easier. We are constantly looking for ways to enhance our portfolio and provide our shareholders with exposure to the best investment opportunities available. Our commitment to seeking out highly skilled, value-creating managers remains unwavering.

Moving forward, we will be introducing a new feature in our reporting.  We will aim to do a deep dive into one of the stocks in our current portfolio. Over time, this will bring the portfolio to life and demonstrate the thoughts and processes that drive the investment decisions from our talented team of fund managers.

I’m also thrilled to highlight the excellent philanthropic contribution that the company has made. Since the inception of Hearts and Minds Investments Ltd in 2018, we have donated more than $43 million to our designated medical research organisations. These contributions have made a significant impact on the lives of many people and will lead to new medical treatments. Personally, I am excited to be part of supporting these important causes and I look forward to learning more about the medical research organisations we support. I will have the privilege of seeing first-hand the incredible work that is being done, and I intend to update you with some of the details of these world class institutions.

Finally, I would like to invite you to get in touch with me here if you have any suggestions about how we can communicate better in the future. We value your feedback and are committed to providing our shareholders with timely and transparent updates on the performance and progress of the company.

Thank you for your ongoing support. I look forward to working with you all to strive to deliver exceptional investment opportunities whilst at the same time supporting some world class medical research here in Australia.

Warm regards,

Charlie

 

Disclaimer: this communication has been prepared by Hearts and Minds Investments Limited (ABN 61 628 753 220) and may contain general information relating to HM1 securities. The general information should not be considered financial advice. HM1 is not licensed to provide financial product advice. The information does not consider the investment objectives, financial situation, or particular needs of any individual. The information is current as at the date of preparation and is subject to change. HM1 does not guarantee repayment of capital or any rate of return on HM1 securities. An investment may achieve a lower-than-expected return and investors risk losing some, or all, of their principal investment. Past performance is not a reliable indicator of future performance. This document may not be reproduced or copies circulated without prior authority from Hearts and Minds Investments Limited.

Hi everyone,

I am delighted to introduce myself as the new Chief Investment Officer of Hearts and Minds Investments. My name is Charlie Lanchester, and I have spent the last 30 years working in the investment industry as a portfolio manager, both in Australia and the UK. I am thrilled to be joining the Hearts and Minds team and look forward to contributing to the growth and success of the fund.

I am aware that the fund has faced some short-term challenges, with a decline in performance contributing to the current share price trading at a significant discount to the net tangible assets (NTA) of the portfolio. While this is disappointing, I feel confident that the underlying investments are sound and that this represents an opportunity to buy some great quality companies at below market price. As an organisation, we have access to some of the brightest minds in the industry, both here in Australia and in global markets. The mix of stocks across sectors and geographies makes this investment proposition quite unique and a great addition to any portfolio. We have a strong bench of talented investment professionals, and I look forward to working closely with them in the coming years.

We are in the process of curating this year's conference, which will return to Sydney on Friday 17th November. We have approached some exciting new fund managers with a particular focus on global opportunities now that travel has become a little easier. We are constantly looking for ways to enhance our portfolio and provide our shareholders with exposure to the best investment opportunities available. Our commitment to seeking out highly skilled, value-creating managers remains unwavering.

Moving forward, we will be introducing a new feature in our reporting.  We will aim to do a deep dive into one of the stocks in our current portfolio. Over time, this will bring the portfolio to life and demonstrate the thoughts and processes that drive the investment decisions from our talented team of fund managers.

I’m also thrilled to highlight the excellent philanthropic contribution that the company has made. Since the inception of Hearts and Minds Investments Ltd in 2018, we have donated more than $43 million to our designated medical research organisations. These contributions have made a significant impact on the lives of many people and will lead to new medical treatments. Personally, I am excited to be part of supporting these important causes and I look forward to learning more about the medical research organisations we support. I will have the privilege of seeing first-hand the incredible work that is being done, and I intend to update you with some of the details of these world class institutions.

Finally, I would like to invite you to get in touch with me here if you have any suggestions about how we can communicate better in the future. We value your feedback and are committed to providing our shareholders with timely and transparent updates on the performance and progress of the company.

Thank you for your ongoing support. I look forward to working with you all to strive to deliver exceptional investment opportunities whilst at the same time supporting some world class medical research here in Australia.

Warm regards,

Charlie

 

Disclaimer: this communication has been prepared by Hearts and Minds Investments Limited (ABN 61 628 753 220) and may contain general information relating to HM1 securities. The general information should not be considered financial advice. HM1 is not licensed to provide financial product advice. The information does not consider the investment objectives, financial situation, or particular needs of any individual. The information is current as at the date of preparation and is subject to change. HM1 does not guarantee repayment of capital or any rate of return on HM1 securities. An investment may achieve a lower-than-expected return and investors risk losing some, or all, of their principal investment. Past performance is not a reliable indicator of future performance. This document may not be reproduced or copies circulated without prior authority from Hearts and Minds Investments Limited.

Disclaimer: This material has been prepared by Hearts & Minds Investments, published on Apr 10, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 19, 2025

HM1 Leadership Restructure

The Board has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.

Read More
June 12, 2025

Coeur Mining – a high-conviction precious metals re-rating story

Coeur Mining provides access to precious metals production in politically stable jurisdictions, with potential for operational and valuation upside.

Read More
March 10, 2025

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
February 20, 2025

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
December 5, 2024

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
Chris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John Feder
November 14, 2024

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 6, 2024

Exploring HM1 Top Stocks: Key Insights from Reporting Season

We have just come to the end of reporting season and the fund managers of our major portfolio holdings gave us their insights into the latest results of our key holdings.

Read More
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
March 7, 2024

Exploring HM1 Stocks: Key Insights from Reporting Season

We asked our fund managers for an update on how some of our key positions are performing off the back of the reporting season. Overall, it was a good period for the fund with some good moves to the upside.

Read More
February 6, 2024

Stock Story: ResMed

This month we take a deep dive into ResMed - one of the conference stocks within the fund that was astutely picked by Chris Kourtis of Ellerston Capital.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.